Probiotic supplementation and systemic inflammation in relapsing-remitting multiple sclerosis: A randomized, double-blind, placebo-controlled trial (vol 16, 901846, 2022)

被引：1
|
作者：
Rahimlou, Mehran [1 ,2 ]
Nematollahi, Shima [1 ]
Husain, Durdana [1 ]
Banaei-Jahromi, Nasrin [3 ]
Majdinasab, Nastaran [4 ]
Hosseini, Seyed Ahmad [1 ]
机构：
[1] Ahvaz Jundishapur Univ Med Sci, Clin Sci Res Inst, Nutr & Metab Dis Res Ctr, Ahvaz, Iran
[2] Zanjan Univ Med Sci, Fac Med, Dept Nutr, Zanjan, Iran
[3] Ahvaz Jundishapur Univ Med Sci, Sch Allied Med Sci, Dept Nutr, Ahvaz, Iran
[4] Ahvaz Jundishapur Univ Med Sci, Sch Med, Dept Neurol, Ahvaz, Iran
来源：
FRONTIERS IN NEUROSCIENCE | 2022年 / 16卷
关键词：
probiotic; multiple sclerosis; inflammation; clinical trial; gut microbiome;
D O I：
10.3389/fnins.2022.1085572
中图分类号：
Q189 [神经科学];
学科分类号：
071006 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial
    Calabresi, Peter A.
    Radue, Ernst-Wilhelm
    Goodin, Douglas
    Jeffery, Douglas
    Rammohan, Kottil W.
    Reder, Anthony T.
    Vollmer, Timothy
    Agius, Mark A.
    Kappos, Ludwig
    Stites, Tracy
    Li, Bingbing
    Cappiello, Linda
    von Rosenstiel, Philipp
    Lublin, Fred D.
    LANCET NEUROLOGY, 2014, 13 (06): : 545 - 556
  • [32] Randomised double-blind placebo-controlled study of interferon β-1a in relapsing-remitting multiple sclerosis (vol 352, pg 1498, 1998)
    Ebers, GC
    McDougall, A
    Frith, J
    LANCET, 1999, 353 (9153): : 678 - 678
  • [33] Baseline Characteristics of Patients in the DEFINE Trial: A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase 3 Study of BG-12 in Relapsing-Remitting Multiple Sclerosis
    Gold, Ralf
    Arnold, Douglas
    Kappos, Ludwig
    Bar-Or, Amit
    Giovannoni, Gavin
    Selmaj, Krzysztof
    Yang, Minhua
    Dawson, Katherine
    NEUROLOGY, 2010, 74 (09) : A546 - A547
  • [34] Vitamin D supplementation and systemic inflammation in relapsing-remitting multiple sclerosis
    Rosjo, Egil
    Steffensen, Linn H.
    Jorgensen, Lone
    Lindstrom, Jonas C.
    Benth, Jurate Saltyte
    Michelsen, Annika E.
    Aukrust, Pal
    Ueland, Thor
    Kampman, Margitta T.
    Torkildsen, Oivind
    Holmoy, Trygve
    JOURNAL OF NEUROLOGY, 2015, 262 (12) : 2713 - 2721
  • [35] Vitamin D supplementation and systemic inflammation in relapsing-remitting multiple sclerosis
    Egil Røsjø
    Linn H. Steffensen
    Lone Jørgensen
    Jonas C. Lindstrøm
    Jūratė Šaltytė Benth
    Annika E. Michelsen
    Pål Aukrust
    Thor Ueland
    Margitta T. Kampman
    Øivind Torkildsen
    Trygve Holmøy
    Journal of Neurology, 2015, 262 : 2713 - 2721
  • [36] INTERFERON BETA-1B IS EFFECTIVE IN RELAPSING-REMITTING MULTIPLE-SCLEROSIS - CLINICAL-RESULTS OF A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
    DUQUETTE, P
    GIRARD, M
    DESPAULT, L
    DUBOIS, R
    KNOBLER, RL
    LUBLIN, FD
    KELLEY, L
    FRANCIS, GS
    LAPIERRE, Y
    ANTEL, J
    FREEDMAN, M
    HUM, S
    GREENSTEIN, JI
    MISHRA, B
    MULDOON, J
    WHITAKER, JN
    EVANS, BK
    LAYTON, B
    SIBLEY, WA
    LAGUNA, J
    KRIKAWA, J
    PATY, DW
    OGER, JJ
    KASTRUKOFF, LF
    MOORE, GRW
    HASHIMOTO, SA
    MORRISON, W
    NELSON, J
    GOODIN, DS
    MASSA, SM
    GUTTERIDGE, E
    ARNASON, BGW
    NORONHA, A
    REDER, AT
    MARTIA, R
    EBERS, GC
    RICE, GPA
    LESAUX, J
    JOHNSON, KP
    PANITCH, HS
    BEVER, CT
    CONWAY, K
    WALLENBERG, JC
    BEDELL, L
    VANDENNOORT, S
    WEINSHENKER, B
    WEISS, W
    REINGOLD, S
    PACHNER, A
    TAYLOR, W
    NEUROLOGY, 1993, 43 (04) : 655 - 661
  • [37] Interferon beta-1b is effective in relapsing-remitting multiple sclerosis I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial
    Sibley, WA
    NEUROLOGY, 2001, 57 (12) : S3 - S9
  • [38] Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis
    Ebers, GC
    Rice, G
    Lesaux, J
    Paty, D
    Oger, J
    Li, DKB
    Beall, S
    Devonshire, V
    Hashimoto, S
    Hooge, J
    Kastrukoff, L
    Krieger, C
    Mezei, M
    Seland, P
    Vorobeychi, G
    Morrison, W
    Nelson, J
    Freedman, MS
    Chrisie, S
    Nelson, R
    Rabinovitch, H
    Freedman, C
    Hartung, HP
    Rieckmann, P
    Archelos, J
    Jung, S
    Weilbach, F
    Flachenecke, P
    Sauer, J
    Hommes, O
    Jongen, P
    Brouwer, S
    McLeod, J
    Pollard, J
    Ng, R
    Sandberg-Wollheim, M
    Källén, K
    Nilsson, P
    Ekberg, R
    Lundgren, A
    Jadbäck, G
    Wikström, J
    Multanen, J
    Valjakka, M
    Carton, H
    Lissoir, F
    Declerq, I
    Vieren, M
    Peeters, E
    Dubois, B
    LANCET, 1998, 352 (9139): : 1498 - 1504
  • [39] Low dose interleukin-2 in relapsing-remitting multiple sclerosis: A randomized double-blinded placebo-controlled trial
    Louapre, C.
    Rosenzwag, M.
    Golse, M.
    Galanaud, D.
    Papeix, C.
    Maillart, E.
    Ungureanu, A.
    Corvol, J. -C.
    Vicaut, E.
    Lubetzki, C.
    Klatzmann, D.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 550 - 551
  • [40] CONCERTO: a placebo-controlled trial of oral laquinimod in patients with relapsing-remitting multiple sclerosis
    Comi, G.
    Vollmer, T. L.
    Boyko, A.
    Vermersch, P.
    Ziemssen, T.
    Montalban, X.
    Lublin, F. D.
    Sasson, N.
    Dadon, Y.
    Steinerman, J. R.
    Knappertz, V.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 74 - 75
12345